Palvella Therapeutics (PVLA) Jones Healthcare and Technology Innovation Conference 2025 summary

Company mission and market focus

• Aims to serve patients with serious, rare genetic skin diseases lacking approved therapies.

• Seeks to become the leader in rare genetic skin diseases, a field with over 600 conditions and only 2% having approved treatments.

• Focuses on diseases with high unmet need and low competitive intensity.

Technology and lead product

• QTORIN is an internally developed platform for novel topical therapies targeting rare genetic skin diseases.

• Lead candidate QTORIN rapamycin is in phase three for two indications and could exceed $1 billion in annual U.S. sales.

• QTORIN rapamycin delivers drug to the dermis, overcoming challenges of oral formulations and compounding.

Microcystic lymphatic malformations (MLM) program

• MLM affects over 30,000 diagnosed U.S. patients, with a $3 billion+ addressable market at orphan pricing.

• No FDA-approved therapies exist; current treatments are invasive and suboptimal.

• QTORIN rapamycin offers a targeted, topical, high-concentration (3.9%) solution with proven safety and efficacy.